CoChat
Sign Up
Cited by 41Pharmacological Receptor Mechanisms and EffectsNeuroscience and Neuropharmacology ResearchNeurotransmitter Receptor Influence on Behavior

Methylphenidate Enhances NMDA-Receptor Response in Medial Prefrontal Cortex via Sigma-1 Receptor: A Novel Mechanism for Methylphenidate Action

Open access
Zhang, Chun-Lei, Feng, Ze-Jun, Liu, Yue, Ji, Xiao-Hua, Peng, Ji-Yun, Zhang, Xue-Han, Zhen, Xue-Chu, Li, Bao-Ming·2012·PLoS ONE
DOI 10.1371/journal.pone.0051910PMC PMC3527396
Open this paper in CoChat — free accountOpen PDF

Abstract

Methylphenidate (MPH), commercially called Ritalin or Concerta, has been widely used as a drug for Attention Deficit Hyperactivity Disorder (ADHD). Noteworthily, growing numbers of young people using prescribed MPH improperly for pleasurable enhancement, take high risk of addiction. Thus, understanding the mechanism underlying high level of MPH action in the brain becomes an important goal nowadays. As a blocker of catecholamine transporters, its therapeutic effect is explained as being due to proper modulation of D1 and α2A receptor. Here we showed that higher dose of MPH facilitates NMDA-receptor mediated synaptic transmission via a catecholamine-independent mechanism, in layer V∼VI pyramidal cells of the rat medial prefrontal cortex (PFC). To indicate its postsynaptic action, we next found that MPH facilitates NMDA-induced current and such facilitation could be blocked by σ1 but not D1/5 and α2 receptor antagonists. And this MPH eliciting enhancement of NMDA-receptor activity involves PLC, PKC and IP3 receptor mediated intracellular Ca(2+) increase, but does not require PKA and extracellular Ca(2+) influx. Our additional pharmacological studies confirmed that higher dose of MPH increases locomotor activity via interacting with σ1 receptor. Together, the present study demonstrates for the first time that MPH facilitates NMDA-receptor mediated synaptic transmission via σ1 receptor, and such facilitation requires PLC/IP3/PKC signaling pathway. This novel mechanism possibly explains the underlying mechanism for MPH induced addictive potential and other psychiatric side effects.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0051910

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • MPH modulates several other proteins including adrenergic, DA and glutamate receptors (ADRA2A, ADRA2B, ADRB1, DRD1, DRD5, DRD2, GRIA1).

    “First, other NT pathways have been reported to be stimulated by MPH, including adrenergic, DA and glutamate receptors (e.g. alpha-2A adrenergic receptor [ADRA2A] and alpha-2B adrenergic receptor [ADRA2B], beta-1 adrenergic receptor [ADRB1], DA receptor 1A [DRD1], DA receptor 1B [DRD5], DA receptor 2 [DRD2]) and glutamate receptor 1 (GRIA1) [142–144].”

    From Molecular Characterisation of the Mechanism of Action of Stimulant Drugs Lisdexamfetamine and Methylphenidate on ADHD Neurobiology: A Review (2022) · cites this paper as [142]

    The Introduction (page unavailable) reports MPH-related activation of α2 and D1 receptors and discusses possible α1 and β1 involvement. The Results (page unavailable) show that MPH enhances NMDA-receptor responses, but that this effect is not directly mediated by D1/5 or α2 receptors. The paper does not establish stimulation of every receptor named in the claim, particularly α2B, D2, or GRIA1; its glutamate-receptor finding concerns NMDA receptors. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

  • In PFC neurons, MPH indirectly activates the postsynaptic DRD1 and DRD5 that uptake DA and transmit the signal in postsynaptic neurons.

    “In PFC neurons, MPH indirectly activates the postsynaptic DRD1 and DRD5 [142] that uptake DA and transmit the signal in postsynaptic neurons [175].”

    From Molecular Characterisation of the Mechanism of Action of Stimulant Drugs Lisdexamfetamine and Methylphenidate on ADHD Neurobiology: A Review (2022) · cites this paper as [142]

    The Introduction says MPH indirectly activates D1 receptors in PFC neurons. It does not establish indirect activation of D5 receptors or identify D1 and D5 as postsynaptic receptors in this claim; the Results instead identify postsynaptic σ1 signaling in the NMDA-receptor response. The later statement about dopamine uptake carries a different citation and is not assessed here. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 96

  1. [1]Arnsten AF (2006) Stimulants: Therapeutic actions in ADHD. Neuropsychopharmacology 31: 2376– 2383. 16855530
  2. [2]Capp PK, Pearl PL, Conlon C (2005) Methylphenidate HCl: therapy for attention deficit hyperactivity disorder. Expert Rev Neurother 5: 325– 331. 15938665
  3. [3]Kempton S, Vance A, Maruff P, Luk E, Costin J, et al (1999) Executive function and attention deficit hyperactivity disorder: stimulant medication and better executive function performance in children. Psychol Med 29: 527– 538. 10405075
  4. [4]Mehta MA, Goodyer IM, Sahakian BJ (2004) Methylphenidate improves working memory and set-shifting in AD/HD: relationships to baseline memory capacity. J Child Psychol Psychiatry 45: 293– 305. 14982243
  5. [6]Gilbert JG, Donnelly KJ, Zimmer LE, Kubis JF (1973) Effect of magnesium pemoline and methylphenidate on memory improvement and mood in normal aging subjects. Int J Aging Hum Dev 4: 35– 51. 4591659
  6. [7]Greely H, Sahakian B, Harris J, Kessler RC, Gazzaniga M, et al (2008) Towards responsible use of cognitive-enhancing drugs by the healthy. Nature 456: 702– 705. 19060880
  7. [8]Mattes JA (1980) The role of frontal lobe dysfunction in childhood hyperkinesis. Compr Psychiatry 21: 358– 369. 6774849
  8. [11]Ferris RM, Tang FL, Maxwell RA (1972) A comparison of the capacities of isomers of amphetamine, deoxypipradrol and methylphenidate to inhibit the uptake of tritiated catecholamines into rat cerebral cortex slices, synaptosomal preparations of rat cerebral cortex, hypothalamus and striatum and into adrenergic nerves of rabbit aorta. J Pharmacol Exp Ther 181: 407– 416. 5033010
  9. [14]Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, et al (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27: 699– 711. 12431845
  10. [15]Spencer RC, Klein RM, Berridge CW (2012) Psychostimulants Act Within the Prefrontal Cortex to Improve Cognitive Function. Biol Psychiatry. PMC3319517 22209638
  11. [19]Gronier B (2011) In vivo electrophysiological effects of methylphenidate in the prefrontal cortex: involvement of dopamine D1 and alpha 2 adrenergic receptors. Eur Neuropsychopharmacol 21: 192– 204. 21146374
  12. [21]Amini B, Yang PB, Swann AC, Dafny N (2004) Differential locomotor responses in male rats from three strains to acute methylphenidate. Int J Neurosci 114: 1063– 1084. 15370174
  13. [22]Yang PB, Swann AC, Dafny N (2006) Dose-response characteristics of methylphenidate on locomotor behavior and on sensory evoked potentials recorded from the VTA, NAc, and PFC in freely behaving rats. Behav Brain Funct 2: 3. 16417623 PMC1360669
  14. [23]Kuczenski R, Segal DS (1997) An escalating dose/multiple high-dose binge pattern of amphetamine administration results in differential changes in the extracellular dopamine response profiles in caudate-putamen and nucleus accumbens. J Neurosci 17: 4441– 4447. 9151761 PMC6573531
  15. [24]Salek RL, Claussen CM, Perez A, Dafny N (2012) Acute and chronic methylphenidate alters prefrontal cortex neuronal activity recorded from freely behaving rats. Eur J Pharmacol 679: 60– 67. 22306242 PMC3293368
  16. [25]Lee MJ, Swann AC, Dafny N (2008) Methylphenidate sensitization is prevented by prefrontal cortex lesion. Brain Res Bull 76: 131– 140. 18395622
  17. [26]Yang PB, Swann AC, Dafny N (2007) Chronic administration of methylphenidate produces neurophysiological and behavioral sensitization. Brain Res 1145: 66– 80. 17335781 PMC1902809
  18. [27]Brookshire BR, Jones SR (2012) Chronic methylphenidate administration in mice produces depressive-like behaviors and altered responses to fluoxetine. Synapse 66: 844– 847. 22588965 PMC3625654
  19. [28]Bolanos CA, Willey MD, Maffeo ML, Powers KD, Kinka DW, et al (2008) Antidepressant treatment can normalize adult behavioral deficits induced by early-life exposure to methylphenidate. Biol Psychiatry 63: 309– 316. 17884021
  20. [29]Lakic A (2012) Depressive symptoms as a side effect of the sustained release form of methylphenidate in a 7-year-old boy with attention-deficit hyperactivity disorder. Vojnosanit Pregl 69: 201– 204. 22500377
  21. [30]Matsumoto RR, Hewett KL, Pouw B, Bowen WD, Husbands SM, et al (2001) Rimcazole analogs attenuate the convulsive effects of cocaine: correlation with binding to sigma receptors rather than dopamine transporters. Neuropharmacology 41: 878– 886. 11684152
  22. [31]Maurice T, Martin-Fardon R, Romieu P, Matsumoto RR (2002) Sigma(1) (sigma(1)) receptor antagonists represent a new strategy against cocaine addiction and toxicity. Neurosci Biobehav Rev 26: 499– 527. 12204195
  23. [32]Nguyen EC, McCracken KA, Liu Y, Pouw B, Matsumoto RR (2005) Involvement of sigma (sigma) receptors in the acute actions of methamphetamine: receptor binding and behavioral studies. Neuropharmacology 49: 638– 645. 15939443
  24. [33]Itzhak Y (1993) Repeated methamphetamine-treatment alters brain sigma receptors. Eur J Pharmacol 230: 243– 244. 8422906
  25. [34]Takahashi S, Miwa T, Horikomi K (2000) Involvement of sigma 1 receptors in methamphetamine-induced behavioral sensitization in rats. Neurosci Lett 289: 21– 24. 10899399
  26. [35]Brammer MK, Gilmore DL, Matsumoto RR (2006) Interactions between 3,4-methylenedioxymethamphetamine and sigma1 receptors. Eur J Pharmacol 553: 141– 145. 17070798 PMC1780037
  27. [37]Vaupel DB (1983) Naltrexone fails to antagonize the sigma effects of PCP and SKF 10,047 in the dog. Eur J Pharmacol 92: 269– 274. 6313397
  28. [38]Su TP (1982) Evidence for sigma opioid receptor: binding of [3H]SKF-10047 to etorphine-inaccessible sites in guinea-pig brain. J Pharmacol Exp Ther 223: 284– 290. 6290634
  29. [39]Largent BL, Gundlach AL, Snyder SH (1986) Pharmacological and autoradiographic discrimination of sigma and phencyclidine receptor binding sites in brain with (+)-[3H]SKF 10,047, (+)-[3H]-3-[3-hydroxyphenyl]-N-(1-propyl)piperidine and [3H]-1-[1-(2-thienyl)cyclohexyl]piperidine. J Pharmacol Exp Ther 238: 739– 748. 3016248
  30. [40]Largent BL, Gundlach AL, Snyder SH (1986) Sigma receptors on NCB-20 hybrid neurotumor cells labeled with (+)[3H]SKF 10,047 and (+)[3H]3-PPP. Eur J Pharmacol 124: 183– 187. 3013658
  31. [41]Bowen WD (2000) Sigma receptors: recent advances and new clinical potentials. Pharm Acta Helv 74: 211– 218. 10812960
  32. [42]Hayashi T, Su TP (2004) Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders. CNS Drugs 18: 269– 284. 15089113
  33. [43]Hayashi T, Su T (2005) The sigma receptor: evolution of the concept in neuropsychopharmacology. Curr Neuropharmacol 3: 267– 280. 18369400 PMC2268997
  34. [44]Monnet FP (2005) Sigma-1 receptor as regulator of neuronal intracellular Ca2+: clinical and therapeutic relevance. Biol Cell 97: 873– 883. 16293108
  35. [45]Yang CR, Seamans JK, Gorelova N (1996) Electrophysiological and morphological properties of layers V-VI principal pyramidal cells in rat prefrontal cortex in vitro. J Neurosci 16: 1904– 1921. 8774458 PMC6578693
  36. [46]Wirkner K, Krause T, Koles L, Thummler S, Al-Khrasani M, et al (2004) D1 but not D2 dopamine receptors or adrenoceptors mediate dopamine-induced potentiation of N-methyl-d-aspartate currents in the rat prefrontal cortex. Neurosci Lett 372: 89– 93. 15531094
  37. [47]Monnet FP, Morin-Surun MP, Leger J, Combettes L (2003) Protein kinase C-dependent potentiation of intracellular calcium influx by sigma1 receptor agonists in rat hippocampal neurons. J Pharmacol Exp Ther 307: 705– 712. 12975497
  38. [48]Martina M, Turcotte ME, Halman S, Bergeron R (2007) The sigma-1 receptor modulates NMDA receptor synaptic transmission and plasticity via SK channels in rat hippocampus. J Physiol 578: 143– 157. 17068104 PMC2075134
  39. [49]Bowen WD, Moses EL, Tolentino PJ, Walker JM (1990) Metabolites of haloperidol display preferential activity at sigma receptors compared to dopamine D-2 receptors. Eur J Pharmacol 177: 111– 118. 2155804
  40. [51]Prezzavento O, Campisi A, Ronsisvalle S, Li Volti G, Marrazzo A, et al (2007) Novel sigma receptor ligands: synthesis and biological profile. J Med Chem 50: 951– 961. 17328523
  41. [52]Cagnotto A, Bastone A, Mennini T (1994) [3H](+)-pentazocine binding to rat brain sigma 1 receptors. Eur J Pharmacol 266: 131– 138. 8157067
  42. [53]Hellewell SB, Bruce A, Feinstein G, Orringer J, Williams W, et al (1994) Rat liver and kidney contain high densities of sigma 1 and sigma 2 receptors: characterization by ligand binding and photoaffinity labeling. Eur J Pharmacol 268: 9– 18. 7925616
  43. [54]Klouz A, Sapena R, Liu J, Maurice T, Tillement JP, et al (2002) Evidence for sigma-1-like receptors in isolated rat liver mitochondrial membranes. Br J Pharmacol 135: 1607– 1615. 11934800 PMC1573292
  44. [55]Gaytan O, Nason R, Alagugurusamy R, Swann A, Dafny N (2000) MK-801 blocks the development of sensitization to the locomotor effects of methylphenidate. Brain Res Bull 51: 485– 492. 10758338
  45. [56]Yang PB, Swann AC, Dafny N (2006) Chronic methylphenidate modulates locomotor activity and sensory evoked responses in the VTA and NAc of freely behaving rats. Neuropharmacology 51: 546– 556. 16824558
  46. [57]Matsumoto RR, Bowen WD, Tom MA, Vo VN, Truong DD, et al (1995) Characterization of two novel sigma receptor ligands: antidystonic effects in rats suggest sigma receptor antagonism. Eur J Pharmacol 280: 301– 310. 8566098
  47. [58]Hayashi T, Maurice T, Su TP (2000) Ca(2+) signaling via sigma(1)-receptors: novel regulatory mechanism affecting intracellular Ca(2+) concentration. J Pharmacol Exp Ther 293: 788– 798. 10869377
  48. [59]Monnet FP, Blier P, Debonnel G, de Montigny C (1992) Modulation by sigma ligands of N-methyl-D-aspartate-induced [3H]noradrenaline release in the rat hippocampus: G-protein dependency. Naunyn Schmiedebergs Arch Pharmacol 346: 32– 39. 1407002
  49. [60]Monnet FP, Debonnel G, Bergeron R, Gronier B, de Montigny C (1994) The effects of sigma ligands and of neuropeptide Y on N-methyl-D-aspartate-induced neuronal activation of CA3 dorsal hippocampus neurones are differentially affected by pertussin toxin. Br J Pharmacol 112: 709– 715. 8075892 PMC1910385
  50. [61]Soriani O, Vaudry H, Mei YA, Roman F, Cazin L (1998) Sigma ligands stimulate the electrical activity of frog pituitary melanotrope cells through a G-protein-dependent inhibition of potassium conductances. J Pharmacol Exp Ther 286: 163– 171. 9655856
  51. [62]Meyer DA, Carta M, Partridge LD, Covey DF, Valenzuela CF (2002) Neurosteroids enhance spontaneous glutamate release in hippocampal neurons. Possible role of metabotropic sigma1-like receptors. J Biol Chem 277: 28725– 28732. 12042305
  52. [63]Maruo J, Yoshida A, Shimohira I, Matsuno K, Mita S, et al (2000) Binding of [35S]GTPgammaS stimulated by (+)-pentazocine sigma receptor agonist, is abundant in the guinea pig spleen. Life Sci 67: 599– 603. 10993125
  53. [64]Morin-Surun MP, Collin T, Denavit-Saubie M, Baulieu EE, Monnet FP (1999) Intracellular sigma1 receptor modulates phospholipase C and protein kinase C activities in the brainstem. Proc Natl Acad Sci U S A 96: 8196– 8199. 10393971 PMC22211
  54. [65]Kim HW, Roh DH, Yoon SY, Seo HS, Kwon YB, et al (2008) Activation of the spinal sigma-1 receptor enhances NMDA-induced pain via PKC- and PKA-dependent phosphorylation of the NR1 subunit in mice. Br J Pharmacol 154: 1125– 1134. 18493253 PMC2465573
  55. [67]Asaoka Y, Nakamura S, Yoshida K, Nishizuka Y (1992) Protein kinase C, calcium and phospholipid degradation. Trends Biochem Sci 17: 414– 417. 1455509
  56. [68]Asaoka Y, Yoshida K, Oka M, Shinomura T, Mishima H, et al.. (1992) The signal-induced phospholipid degradation cascade and protein kinase C activation. Ciba Found Symp 164: 50–59; discussion 59–65. 1395935
  57. [69]Nishizuka Y (1995) Protein kinase C and lipid signaling for sustained cellular responses. Faseb J 9: 484– 496. 7737456
  58. [70]Yang P, Swann A, Dafny N (2000) NMDA receptor antagonist disrupts acute and chronic effects of methylphenidate. Physiol Behav 71: 133– 145. 11134695
  59. [71]Prieto-Gomez B, Vazquez-Alvarez AM, Martinez-Pena JL, Reyes-Vazquez C, Yang PB, et al (2005) Methylphenidate and amphetamine modulate differently the NMDA and AMPA glutamatergic transmission of dopaminergic neurons in the ventral tegmental area. Life Sci 77: 635– 649. 15921995
  60. [73]Husson I, Mesples B, Medja F, Leroux P, Kosofsky B, et al (2004) Methylphenidate and MK-801, an N-methyl-d-aspartate receptor antagonist: shared biological properties. Neuroscience 125: 163– 170. 15051155
  61. [74]Wang J, O’Donnell P (2001) D(1) dopamine receptors potentiate nmda-mediated excitability increase in layer V prefrontal cortical pyramidal neurons. Cereb Cortex 11: 452– 462. 11313297
  62. [75]Gurden H, Takita M, Jay TM (2000) Essential role of D1 but not D2 receptors in the NMDA receptor-dependent long-term potentiation at hippocampal-prefrontal cortex synapses in vivo. J Neurosci 20: RC106. 11069975 PMC6773154
  63. [76]Navarro G, Moreno E, Aymerich M, Marcellino D, McCormick PJ, et al (2010) Direct involvement of sigma-1 receptors in the dopamine D1 receptor-mediated effects of cocaine. Proc Natl Acad Sci U S A 107: 18676– 18681. 20956312 PMC2972946
  64. [77]Fu Y, Zhao Y, Luan W, Dong LY, Dong Y, et al (2010) Sigma-1 receptors amplify dopamine D1 receptor signaling at presynaptic sites in the prelimbic cortex. Biochim Biophys Acta 1803: 1396– 1408. 20732358
  65. [78]Ujike H, Kuroda S, Otsuki S (1996) sigma Receptor antagonists block the development of sensitization to cocaine. Eur J Pharmacol 296: 123– 128. 8838447
  66. [79]Bergeron R, de Montigny C, Debonnel G (1996) Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors. J Neurosci 16: 1193– 1202. 8558248 PMC6578822
  67. [80]Monnet FP, Debonnel G, Fournier A, de Montigny C (1992) Neuropeptide Y potentiates the N-methyl-D-aspartate response in the CA3 dorsal hippocampus. II. Involvement of a subtype of sigma receptor. J Pharmacol Exp Ther 263: 1219– 1225. 1469630
  68. [81]Debonnel G, Bergeron R, de Montigny C (1996) Potentiation by dehydroepiandrosterone of the neuronal response to N-methyl-D-aspartate in the CA3 region of the rat dorsal hippocampus: an effect mediated via sigma receptors. J Endocrinol 150 Suppl: S33–42 8943785
  69. [82]Monnet FP, Debonnel G, Junien JL, De Montigny C (1990) N-methyl-D-aspartate-induced neuronal activation is selectively modulated by sigma receptors. Eur J Pharmacol 179: 441– 445. 2163857
  70. [83]Han DD, Gu HH (2006) Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol 6: 6. 16515684 PMC1448202
  71. [84]Swanson JM, Volkow ND (2003) Serum and brain concentrations of methylphenidate: implications for use and abuse. Neurosci Biobehav Rev 27: 615– 621. 14624806
  72. [85]Wang JQ, Liu X, Zhang G, Parelkar NK, Arora A, et al (2006) Phosphorylation of glutamate receptors: a potential mechanism for the regulation of receptor function and psychostimulant action. J Neurosci Res 84: 1621– 1629. 16983660
  73. [86]Pascoli V, Valjent E, Corbille AG, Corvol JC, Tassin JP, et al (2005) cAMP and extracellular signal-regulated kinase signaling in response to d-amphetamine and methylphenidate in the prefrontal cortex in vivo: role of beta 1-adrenoceptors. Mol Pharmacol 68: 421– 429. 15890841
  74. [87]Chiu HY, Lin HH, Lai CC (2009) Potentiation of spinal NMDA-mediated nociception by cocaine- and amphetamine-regulated transcript peptide via PKA and PKC signaling pathways in rats. Regul Pept 158: 77– 85. 19632277
  75. [88]Arnsten AF, Ramos BP, Birnbaum SG, Taylor JR (2005) Protein kinase A as a therapeutic target for memory disorders: rationale and challenges. Trends Mol Med 11: 121– 128. 15760770
  76. [89]Micheau J, Riedel G (1999) Protein kinases: which one is the memory molecule? Cell Mol Life Sci 55: 534– 548. 10357224 PMC11337859
  77. [91]Brennan AR, Dolinsky B, Vu MA, Stanley M, Yeckel MF, et al (2008) Blockade of IP3-mediated SK channel signaling in the rat medial prefrontal cortex improves spatial working memory. Learn Mem 15: 93– 96. 18285467 PMC2275660
  78. [92]Ishisaka M, Kakefuda K, Oyagi A, Ono Y, Tsuruma K, et al (2012) Diacylglycerol kinase beta knockout mice exhibit attention-deficit behavior and an abnormal response on methylphenidate-induced hyperactivity. PLoS One 7: e37058. 22590645 PMC3349656
  79. [93]Dopheide JA, Pliszka SR (2009) Attention-deficit-hyperactivity disorder: an update. Pharmacotherapy 29: 656– 679. 19476419
  80. [94]Teyler TJ (1987) Long-term potentiation and memory. Int J Neurol 21–22: 163– 171. 2856550
  81. [95]Shapiro M (2001) Plasticity, hippocampal place cells, and cognitive maps. Arch Neurol 58: 874– 881. 11405801
  82. [96]Niitsu T, Iyo M, Hashimoto K (2012) Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases. Curr Pharm Des 18: 875– 883. 22288409
  83. [97]Cobos EJ, Entrena JM, Nieto FR, Cendan CM, Del Pozo E (2008) Pharmacology and therapeutic potential of sigma(1) receptor ligands. Curr Neuropharmacol 6: 344– 366. 19587856 PMC2701284
  84. [99]Li Z, Zhou R, Cui S, Xie G, Cai W, et al (2006) Dehydroepiandrosterone sulfate prevents ischemia-induced impairment of long-term potentiation in rat hippocampal CA1 by up-regulating tyrosine phosphorylation of NMDA receptor. Neuropharmacology 51: 958– 966. 16895729
  85. [100]Bergeron R, Debonnel G, De Montigny C (1993) Modification of the N-methyl-D-aspartate response by antidepressant sigma receptor ligands. Eur J Pharmacol 240: 319– 323. 8243549
  86. [101]Nuwayhid SJ, Werling LL (2003) Sigma1 receptor agonist-mediated regulation of N-methyl-D-aspartate-stimulated [3H]dopamine release is dependent upon protein kinase C. J Pharmacol Exp Ther. 304: 364– 369. 12490613
  87. [102]Gonzalez GM, Werling LL (1997) Release of [3H]dopamine from guinea pig striatal slices is modulated by sigma1 receptor agonists. Naunyn Schmiedebergs Arch Pharmacol 356: 455– 461. 9349631
  88. [103]Hayashi T, Su TP (2008) An update on the development of drugs for neuropsychiatric disorders: focusing on the sigma 1 receptor ligand. Expert Opin Ther Targets 12: 45– 58. 18076369
  89. [104]Dolder CR, Davis LN, McKinsey J (2010) Use of psychostimulants in patients with dementia. Ann Pharmacother 44: 1624– 1632. 20736422
  90. [105]Kaufmann MW, Cassem NH, Murray GB, Jenike M (1984) Use of psychostimulants in medically ill patients with neurological disease and major depression. Can J Psychiatry 29: 46– 49. 6704886
  91. [106]Arcand M, Hottin P (1993) [Treatment of depression in the elderly. The use of psychostimulants]. Can Fam Physician 39: 2420– 2426. 8268747 PMC2379921
  92. [107]Ji XH, Cao XH, Zhang CL, Feng ZJ, Zhang XH, et al (2008) Pre- and postsynaptic beta-adrenergic activation enhances excitatory synaptic transmission in layer V/VI pyramidal neurons of the medial prefrontal cortex of rats. Cereb Cortex 18: 1506– 1520. 17965126
  93. [108]Barnum DW (1977) Spectrophotometric determination of catechol, epinephrine, dopa, dopamine and other aromatic vic-diols. Anal Chim Acta 89: 157– 166. 842863
  94. [109]Maier CA, Wunsch B (2002) Novel spiropiperidines as highly potent and subtype selective sigma-receptor ligands. Part 1. J Med Chem 45: 438– 448. 11784148
  95. [110]Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265– 275. 14907713
  96. [111]Cheng HC (2001) The power issue: determination of KB or Ki from IC50. A closer look at the Cheng-Prusoff equation, the Schild plot and related power equations. J Pharmacol Toxicol Methods 46: 61– 71. 12481843

Cited by

Sorted by citations

Authors
Zhang, C.-L., Feng, Z.-J., Liu, Y., Ji, X.-H., Peng, J.-Y., Zhang, X.-H., Zhen, X.-C., & Li, B.-M.
Affiliations
  • Fudan University (CN)
  • Chinese Academy of Sciences (CN)
  • Nanchang University (CN)
Corresponding author
Li, Bao-Ming
ORCID
Venue
PLoS ONE
Publisher
Public Library of Science (PLoS)
Published
2012-12-20
Volume
7
Issue
12
Pages
e51910
ISSN
1932-6203 (ISSN-L)
DOI
10.1371/journal.pone.0051910
PMC
PMC3527396
OpenAlex
W2009896968
Cited by
41
References
15
Citations by year
2025: 5 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 4 · 2019: 3 · 2018: 4 · 2017: 1 · 2016: 3 · 2015: 7 · 2014: 5 · 2013: 1
FWCI
1.67
Type
journal article
Language
en
Open access
Licence
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (30821002, 30700218, 30990263)
  • Chinese Academy of Sciences
  • Fudan University
  • State Key Laboratory of Medical Neurobiology
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pharmacological Receptor Mechanisms and Effects
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
methylphenidate, sigma-1 receptor, NMDA receptor, medial prefrontal cortex, synaptic transmission, intracellular calcium, locomotor activity, attention deficit hyperactivity disorder, drug addiction, dopamine D1 receptor, alpha2A-adrenergic receptor
MeSH terms
Sigma-1 Receptor, Central Nervous System Stimulants, Animals, Calcium, Catecholamines, Methylphenidate, Motor Activity, Synaptic Transmission, Protein Binding, Protein Kinase C, Synapses, Signal Transduction, Receptors, N-Methyl-D-Aspartate, Prefrontal Cortex, Receptors, sigma, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review